Virtu Financial LLC Has $45,000 Stake in Seer, Inc. (NASDAQ:SEER)

Virtu Financial LLC trimmed its stake in Seer, Inc. (NASDAQ:SEER) by 54.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,076 shares of the company’s stock after selling 27,221 shares during the quarter. Virtu Financial LLC’s holdings in Seer were worth $45,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. AQR Capital Management LLC acquired a new position in Seer in the 2nd quarter valued at approximately $30,000. Point72 DIFC Ltd purchased a new position in shares of Seer during the 2nd quarter valued at $35,000. American Century Companies Inc. increased its stake in shares of Seer by 42.1% in the second quarter. American Century Companies Inc. now owns 61,752 shares of the company’s stock worth $104,000 after acquiring an additional 18,302 shares during the last quarter. Quadrature Capital Ltd raised its holdings in shares of Seer by 301.7% during the third quarter. Quadrature Capital Ltd now owns 57,088 shares of the company’s stock worth $112,000 after acquiring an additional 42,875 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Seer during the third quarter valued at $123,000. 75.20% of the stock is currently owned by institutional investors and hedge funds.

Seer Price Performance

Shares of SEER stock opened at $2.31 on Friday. The firm has a market cap of $136.21 million, a P/E ratio of -1.78 and a beta of 1.58. Seer, Inc. has a fifty-two week low of $1.51 and a fifty-two week high of $2.63. The stock’s 50-day moving average is $2.24 and its two-hundred day moving average is $1.93.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.